References
- Nakamoto Y, Tabuchi Y, Saeki S, et al. Cushing’s syndrome found during long-term glucocorticoid treatment of rheumatoid arthritis in an elderly woman. Jpn J Geriat. 1992;29:54–58.
- Senécal JL, Uthman I, Beauregard H. Cushing’s disease-induced remission of severe rheumatoid arthritis. Arthritis Rheum. 1994;37:1826.
- Yakushiji F, Kita M, Hiroi N, et al. Exacerbation of rheumatoid arthritis after removal of adrenal adenoma in Cushing’s syndrome. Endocr J. 1995;42:219–223.
- Shimizu M, Kawata M, Okada T, et al. Concomitant Cushing’s Syndrome due to adrenal adenoma in a patient with systemic lupus erythematosus. Intern Med. 2002;41:1044–1046.
- Arima K, Higuchi M, Yoshizawa S, et al. Improvement of systemic lupus erythematosus activity by the association of delayed onset Cushing’s syndrome. J Rheumatol. 1998;25:2456–2458.
- Katayama A, Otsuka F, Tanabe K, et al. Unexpected occurrence of adrenal Cushing’s syndrome in a patient with systemic lupus erythematosus. Hypertens Res. 2011;34:662–663.
- Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93:1526–1540.
- Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677–2686.
- Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35:630–640.
- Stoll T, Stucki G, Malik J, et al. Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus. Ann Rheum Dis. 1996;55:756–760.
- Hammond GL. Molecular properties of corticosteroid binding globulin and the sex-steroid binding proteins*. Endocr Rev. 1990;11:65–79.
- Zietz B, Reber T, Oertel M, et al. Altered function of the hypothalamic stress axes in patients with moderately active systemic lupus erythematosus. II. Dissociation between androstenedione, cortisol, or dehydroepiandrosterone and interleukin 6 or tumor necrosis factor. J Rheumatol. 2000;27:911–918.
- Jäättelä M, Ilvesmäki V, Voutilainen R, et al. Tumor necrosis factor as a potent inhibitor of adrenocorticotropin-induced cortisol production and steroidogenic P450 enzyme gene expression in cultured human fetal adrenal cells. Endocrinology. 1991;128:623–629.
- Straub RH, Weidler C, Demmel B, et al. Renal clearance and daily excretion of cortisol and adrenal androgens in patients with rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis. 2004;63:961–968.